Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022
Sonja Pleininger, Alexander Indra, Daniel Golparian, Florian Heger, Stefanie Schindler, Susanne Jacobsson, Stefan Heidler, Magnus Unemo
Abstract
We describe a gonorrhoea case with ceftriaxone plus high-level azithromycin resistance. In April 2022, an Austrian heterosexual male was diagnosed with gonorrhoea after sexual intercourse with a female sex worker in Cambodia. Recommended treatment with ceftriaxone (1 g) plus azithromycin (1.5 g) possibly failed. Worryingly, this is the second strain in an Asian Neisseria gonorrhoeae genomic sublineage including high-level azithromycin-resistant strains that developed ceftriaxone resistance by acquisition of mosaic penA -60.001. Enhanced resistance surveillance and actions are imperative to prevent spread.
Topics & Concepts
CeftriaxoneAzithromycinNeisseria gonorrhoeaeMen who have sex with menMedicineGonorrheaAntibiotic resistanceDrug resistanceMicrobiologySyphilisVirologyInternal medicineAntibioticsBiologyHuman immunodeficiency virus (HIV)Reproductive tract infections researchSyphilis Diagnosis and TreatmentVirology and Viral Diseases